(NASDAQ: ELDN) Eledon Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.37%.
Eledon Pharmaceuticals's earnings in 2026 is -$45,617,000.On average, 8 Wall Street analysts forecast ELDN's earnings for 2026 to be -$70,405,568, with the lowest ELDN earnings forecast at -$72,104,647, and the highest ELDN earnings forecast at -$65,308,333. On average, 6 Wall Street analysts forecast ELDN's earnings for 2027 to be -$67,568,714, with the lowest ELDN earnings forecast at -$75,078,034, and the highest ELDN earnings forecast at -$63,715,446.
In 2028, ELDN is forecast to generate -$71,179,256 in earnings, with the lowest earnings forecast at -$68,387,913 and the highest earnings forecast at -$73,272,763.